Goldman Sachs Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $18

Goldman Sachs analyst Madhu Kumar maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $64 to $18.

Goldman Sachs analyst Madhu Kumar maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $64 to $18.

Total
0
Shares
Related Posts